Objectives: The main objective of this study was to analyze treatment patterns of elderly patients with breast cancer brain metastases (BCBM), evaluate characteristics associated with treatment selection, and to analyze trends in overall survival (OS) over time.
B
reast cancer (BC) is one of the most frequent causes of brain metastases (BM). The overall rate ranges between 10% and 16% of metastatic patients, 1 but an additional 10% to 15% clinically asymptomatic cases have been detected by autopsy studies. 2, 3 In recent years, BM have become a more common clinical problem, 4 likely attributable to improved overall survival (OS) and to better detection of brain lesions.
Previous studies have found that patients with triple-negative or human epidermal growth factor receptor 2 (HER2) positive tumors have an increased risk for the development of BM. [5] [6] [7] BM are associated with poor prognosis, 8, 9 but data from more recent studies suggest that multimodality treatments to the brain may lead to improved outcomes. [10] [11] [12] Treatment options for patients with BCBM include surgical resection, whole-brain radiotherapy, stereotactic radiosurgery, and chemotherapy, and these treatment modalities have improved over the past decade. For example, improvement in the knowledge of risk factors for cranial surgery has led to better patient selection. 13 There are also newer and more specific radiation techniques that are associated with less toxicity. 14 Finally, there are an increasing number of chemotherapy options, some of which can cross the blood-brain barrier. 15 Despite these advances, there is no data on how we use these treatments in practice and whether there has been a change in OS over time.
The present population-based study was designed with 2 aims: (1) to analyze treatment patterns of elderly patients with BCBM and evaluate characteristics associated with treatment selection; and (2) to analyze trends in OS over time to assess if OS has improved.
MATERIALS AND METHODS

Data Sources
We used data from the Surveillance, Epidemiology, and End Results (SEER) Program linkage to Medicare claims (SEER-Medicare). Established in 1973, SEER comprises cancer registries across the United States that identify and document cancer cases in their respective catchment areas. As of 2017, SEER covers~28% of the United States population. 16 The SEER-Medicare linkage is performed by the National Cancer Institute and matches 93% of people 65 years of age and older in the SEER database with their Medicare claims data. 17 
Cohort Selection
Patients were diagnosed with primary BC between 1973 and 2012 (per SEER data) and subsequent BM (per Medicare claims data). Patients with any primary cancer other than BC were excluded. For patients with multiple primary BC, the cancer closest in time and preceding the BM diagnosis was defined as the "index" cancer.
Identification of BM was conducted by searching inpatient, outpatient facility, and professional claims files for international classification of diseases ninth revision (ICD-9) diagnosis code 198.3 for BM. Inclusion required at least (1) one occurrence of a BM diagnosis code in inpatient claims or (2) ≥ 2 occurrences of a BM diagnosis code at least 30 days apart and no > 365 days apart in professional or outpatient facility claims. We adopted the criteria for outpatient/professional claims to eliminate "rule-out" diagnoses.
Participants were further excluded if the claim with the first BM diagnosis was dated before the index BC diagnosis date or on or after the date of death, or if the first BM claim occurred before the participants were 66 years of age. Finally, we required participants to have continuous Medicare Parts A and B and no HMO coverage for at least 365 days before their first BM diagnosis date and for at least 60 days after their first BM diagnosis date.
Other exclusion criteria included: male sex, missing month of BC diagnosis, discordance between Medicare and SEER dates of death and/or birth, index BC diagnosis not confirmed microscopically, and BC diagnosis from autopsy or from death certificate (Fig. 1) .
Patient Characteristics and Treatment
Demographic and clinical characteristics of patients were determined from SEER data. For women with > 1 diagnosis of BC, we examined the characteristics from the index BC. These characteristics included stage at diagnosis (using both SEER historic stage and the Breast Adjusted AJCC Sixth Stage), estrogen and progesterone receptor status (ER and PR, respectively).
The date of the first claim with a BM diagnosis code was taken to be the date of the BM diagnosis. Date of first treatment was taken to be the date of the claim with the first occurrence of a specified ICD-9 or health care common procedure coding system code (Table 1 ) on or after the BM diagnosis date.
Separate first treatment dates were calculated for resection, chemotherapy, and radiation. Claims in the 60 days following BM diagnosis were examined to place patients in the following treatment groups: resection only, radiation only, chemotherapy only, combination of ≥ 2 treatments, or no treatment (Table 1) .
Comorbidities were identified using claims from inpatient, outpatient facility, and professional files for conditions identified by Charlson et al 18 and adapted by Deyo et al 19 and Klabunde et al. 20 To examine the potential effect that contact with an academic medical center (AMC) might have on treatment and outcomes, we searched for any claim filed with a GC modifier to a health care common procedure coding system or CPT code in the 365 days before until 60 days after first BM diagnosis. The GC modifier is appended to any claim where "(the) service has been performed in part by a resident under the direction of a teaching physician," and must be accompanied by a written statement from the teaching physician to that effect. 21 In the context of this report, this variable indicates having received any care at an AMC during the period described.
Statistical Analyses
Cochran-Armitage tests were used to identify whether the proportion of patients receiving each treatment modality differed across time. A multinomial logistic regression model was applied to determine the effects of sociodemographic and clinicopathologic variables on modality of treatment received, with no treatment serving as the reference category. Estimated effects are reported as odds ratios (OR) along with 95% confidence intervals (95% CI). Cox regression models were used to determine OS trends within each treatment modality across time while adjusting for sociodemographic and clinicopathologic characteristics. Time was calculated from date of BM to death. Patients still alive at the end of 2013 were censored. Estimated effects are reported as hazard ratios (HRs) along with 95% CI. All tests were 2-sided and assessed for significance at the 5% level using SAS v9.4 (SAS Institute, Cary, NC).
RESULTS
Patient Characteristics
A total of 5969 women were diagnosed with BCBM between 1992 and 2012 and were included in this study. Median age at BM diagnosis was 74.1 years (range, 66.0 to 100.1). Median interval from diagnosis of index BC until development of BM was 3.7 years (range, 0 to 37.1). Most patients had extracranial metastases (78.5%; n = 4683) and lacked comorbidities (55.6%; n = 3317). Among patients with known hormone receptor status, 2733 patients (68.5%) had ERpositive tumors and 2120 patients (54%) had PR-positive tumors. Table 2 shows the distribution of patient characteristics overall and according to type of treatment. Not receiving treatment was common (42.2%; n = 2517), followed by receiving radiation only (27.1%; n = 1619), a combination of ≥ 2 treatments (17.1%; n = 1024), chemotherapy only (10.1%; n = 602) and resection only (3.5%; n = 207). Among the 1024 patients who received combination of ≥ 2 treatments, 661 patients (64.6%) were treated with radiation and chemotherapy, 265 patients (25.9%) were treated with resection and radiation, 33 patients (3.2%) were treated with resection and chemotherapy, and 65 patients (6.3%) were treated with resection, radiation, and chemotherapy.
Treatment Patterns and Trends
The changes in treatment over time are shown in Figure 2 . Although most patients were untreated for their BM, the proportion untreated fell from 50% in 1992 to 35.9% in 2012 (P for trend <0.01). The form of treatment that increased the most was using a combination of ≥ 2 treatments, which increased from 8.8% in 1992 to 18% in 2012 (P for trend <0.01). Although less markedly, the use of radiation only also increased significantly over time (P for trend = 0.03), and there was a small increase in chemotherapy only which did not reach statistical significance (P for trend = 0.06). Finally, the percent of patients receiving resection only remained stable across time (P for trend = 0.49).
Characteristics Associated With BM Treatments
After adjustment, patients of white race, with extracranial metastases, negative receptor status, more recently diagnosed with BM, and who were not seen at an AMC were significantly more likely to receive treatments (Table 3) . Specifically, the presence of extracranial metastases was associated with higher odds of receiving chemotherapy only (OR, 14.25), radiation only (OR, 3.87), and combination of ≥ 2 treatments (OR, 5.47). In contrast, older patients, those with more comorbid conditions, unmarried or eligible for Medicare because of disability or ESRD were generally less likely to be treated (Table 3) .
OS
After a median follow-up of 11.8 months (range, 2.0 to 257.6), 5219 deaths were reported. Median OS for the entire cohort was 11.8 months (95% CI, 11. (Fig. 3) .
To assess changes in OS over time, an interaction between treatment and year of BM diagnosis was evaluated in the multivariable model. The interaction was significant (P < 0.01) and showed that risk of death decreased over time for the group of patients who received the combination of ≥ 2 treatments (HR, 0.89 per every 5 y of diagnosis; 95% CI, 0.84-0.95). In contrast, the group of patients who received no treatment had an increased risk of death over time with a HR of 1.06 per every 5 years of diagnosis (95% CI, 1.02-1.11) (Fig. 3 ). An exploratory analysis was conducted to evaluate the reasons behind the OS deterioration in the untreated group, and this analysis revealed that the number of comorbid conditions among untreated patients had increased over time as shown in Figure 1 in the Supplemental Digital Content 1 (http://links.lww.com/AJCO/A223) while other patient characteristics remained stable (data not shown).
DISCUSSION
BM are a common occurrence in BC, representing the fourth most common site of distant metastatic spread. 22 Most data on treatment and outcomes come from small retrospective studies. In this population-based study we found that the proportion of patients treated for BM increased from 50% in 1992 to 64.1% in 2012. There have been significant changes in treatment use over time. We observed increases in combined treatment with ≥ 2 therapies and increases in radiation only. There was a reduction in the proportion of patients receiving no treatment. These changes persisted on multivariable analysis, suggesting that these trends are not attributable to clinical or sociodemographic characteristics of patients with BM. In contrast, the use of chemotherapy only or resection only did not change significantly.
Several factors were associated with treatment selection. Both older age and higher number of comorbidities were independently associated with lower odds of receiving any form of treatment. Patients with extracranial metastases had 14.2 times higher odds of receiving chemotherapy only, which can treat the systemic disease as well as BM. Patients with hormone receptor-negative tumors had twice the odds of receiving the combination of ≥ 2 treatments, a finding that is consistent with the more aggressive behavior of this tumor subtype.
OS in patients with BCBM has been uniformly poor, as demonstrated by recent reports. 23, 24 Consistent with these findings, median OS of our cohort was 11.8 months. Two recent observational trials of patients with HER2-positive metastatic BC-SystHERs and registHER-have reported median OS for patients with BCBM of 22 months and 27 months, respectively. 25, 26 The longer OS reported by these studies compared with our results, may be explained in part due to the inclusion of other subtypes of BC in our study, such as triplenegative BC and HER2-negative BC, which are known to have worse OS. 27 Other factors that contribute to the discrepancy in OS include the older age of our population and the higher rate of no treatment use. In fact, in the registHER study, patients who were not treated with trastuzumab, chemotherapy, radiotherapy, or surgery had a median OS of 3.8 months, 3.7 months, 8.4 months, and 11.3 months, respectively. 26 Our study showed that OS has improved significantly over time among patients treated with combination therapy. In contrast, outcomes have not changed for patients treated with single modalities, and OS for untreated patients has significantly worsened over time. These changes could be due in part to improvements in multimodality treatment strategies and to the possibility that providers are more effectively adapting those treatments for people who previously had been poor candidates for therapy. This possibility is supported by the observation that there have been an increasing number of comorbidities in untreated patients; only the sickest of the sick appear to go untreated in more recent years, and the observed higher risk of death could reflect the fact that untreated patients are less healthy on the average than they were in the past.
Controversy exists around the impact of extracranial disease in patients with BCBM. Our results showed that the presence of extracranial metastases was the strongest predictor of poorer OS with a HR of 2.19. This is important given that extracranial disease was not included in the final model of the BC-specific graded prognostic assessment-a prognostic tool for patients with BCBM. 28 Other parameters that were associated with OS in the multivariable Cox models included marital status, comorbidities, stage, ER/PR status, and age. These have been commonly observed prognostic factors in patients with BCBM. 26, 27 Our findings with regard to the treatment setting of BC care are provocative. After adjustment for clinical and sociodemographic characteristics, patients who were not seen at an AMC were more likely to be treated, but they had worse OS. Future studies with more detailed data about BM surveillance and treatment could shed light on care processes and/or clinical characteristics that may explain this apparent disadvantage.
We acknowledge that our study has some limitations. The sensitivity of our claims-based definition of BM is unknown, and potential members of our cohort could have gone unidentified. Although 2 other SEER-Medicare papers 29, 30 have applied a similar approach to identifying BM, the positive predictive value of the algorithm has not been studied in BC. However, we have no reason to expect gradual changes in positive predictive value over time that would be necessary to explain the temporal patterns we observed. Although this approach also did not allow us to determine whether BM were microscopically confirmed, we excluded patients who had diagnoses of other primary malignancies to maximize the possibility that the BM originated from BC. Lack of information on HER2 status is another limitation.
The specific anatomic site treated with radiation therapy is not discernible from Medicare claims data. In order to maximize the likelihood that the therapy was directed at the brain, we only included those claims dated between the point of BM diagnosis until 60 days after, similar to Halasz et al. 30 Although this algorithm was validated for BM from lung cancer, it has not been validated for BCBM. Finally, we only examined chemotherapy that was administered in inpatient or outpatient facilities, which do not include many orally administered chemotherapies. This could have caused underreporting of oral chemotherapy.
Despite these limitations, our study has several important strengths. To our knowledge, this is the largest analysis of treatment patterns and outcomes in BCBM conducted to date. The use of Medicare claims data represents a reliable source of information to analyze treatment administration. In addition, this population-based cohort provides extremely valuable information about the management of patients with BCBM in both academic and community settings.
In summary, in this large study of patients with BCBM we observed substantial changes in treatment patterns and OS over time. There were significant increases in the administration of combination therapy with ≥ 2 treatments and in radiation therapy and a meaningful decrease in the proportion of patients receiving no treatment. Patients who underwent combination of ≥ 2 treatments had a significant improvement in OS over time. Our study identified several factors associated with BCBM treatment and survival which suggest potentially fruitful areas for continuing to improve OS after BM.
